September 20 - 23, 2014
Sheraton Philadelphia Downtown
Philadelphia, Pa., USA
Abstract submission deadline: Friday, August 8
Advance registration deadline: Monday, August 4
Sept. 20-23, 2014Sheraton Philadelphia DowntownPhiladelphia, Pa.
Late-Breaking Abstract Submission Deadline: Friday, Aug. 8
Advance registration deadline: Monday, Aug. 4, 2014
Conference ChairpersonKenneth C. Anderson, Dana-Farber Cancer Institute, Boston, Mass.
Conference Co-ChairpersonsScott A. Armstrong, Memorial Sloan Kettering Cancer Center, New York, N.Y.Riccardo Dalla-Favera, Columbia University Institute for Cancer Genetics, New York, N.Y.
The AACR is proud to announce a new Special Conference focused on the blood-based cancers and associated disorders categorized as hematologic malignancies and will include presentations pertaining to leukemia, lymphoma, myeloma, myelodysplastic syndrome, and myeloproliferative neoplasms. This conference will span the spectrum of relevant cancer science and medicine, from basic science discoveries to their translation in the clinic, and will cover those scientific areas that cut across all blood cancers such as genomics, epigenetics, cell death pathways, and the tumor microenvironment, as well as translational and clinical topics such as targetable signaling pathways, drug development, immunotherapy, other treatment modalities, and early clinical trials.
This conference offers a unique opportunity for a lively discussion, in a small setting, of the challenges in the field among basic, translational, and clinical researchers and for potential collaborations among national and international investigators in the field. The chairpersons and members of the Scientific Program Committee for this Special Conference are world-renowned experts in the diverse areas of the field. Under their leadership, the meeting will provide an outstanding forum for the presentation of today’s most exciting developments in the research and treatment of hematologic malignancies. In addition, the major goals of this AACR conference are to highlight the common aspects of both hematologic malignancies and solid tumors and to foster new knowledge and creative ideas about how to treat and cure these diseases.
Scientific Program Committee